Bone Biologics plans to raise up to $9 million through a private placement of common stock, priced at-the-market under Nasdaq rules, to fund development efforts.
Bone Biologics Announces Up To $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
